DRG Market Assessment reports

DRG Epidemiology’s coverage of cervical cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of cervical…

DRG Epidemiology’s coverage of cervical cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of cervical…

DRG Epidemiology’s coverage of cervical cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of cervical…

DRG Epidemiology’s coverage of cervical cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of cervical…

DRG Epidemiology’s coverage of cervical cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of cervical…

The DR / DME therapy market will grow moderately over the forecast period (6.6% annual growth through 2029); this growth will be due largely to: The launch of five new therapeutic options…

DRG Epidemiology’s coverage of osteoarthritis (OA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OA in each country, as…

DRG Epidemiology’s coverage of osteoarthritis (OA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OA in each country, as…

DRG Epidemiology’s coverage of osteoarthritis (OA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OA in each country, as…

DRG Epidemiology’s coverage of osteoarthritis (OA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OA in each country, as…

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia (AML). Although…

Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the second half of…